Key result
Rivaroxaban successfully prevented thromboembolic events during the perioperative period in a 90-year-old woman with antithrombin deficiency, with no events occurring for at least three months.
Why the study?
Does rivaroxaban prevent thromboembolism in a patient with antithrombin deficiency during the perioperative period?
Case Report (n=1)
No
Does rivaroxaban prevent thromboembolism in a patient with antithrombin deficiency during the perioperative period?
Rivaroxaban was successfully used to prevent perioperative thromboembolism in a 90-year-old woman with antithrombin deficiency.
Supports perioperative rivaroxaban feasibility in AT deficiency; hypothesis-generating and requires prospective validation before practice change.
Antithrombin (AT) deficiency, a rare disorder of the coagulation system, is a serious risk factor for thromboembolism. Approximately 50-90% of patients with AT deficiency develop thromboembolism during their lifetime. In addition, surgery is a major risk factor for thromboembolism in these patients. We herein report the case of a 90-year-old woman with AT deficiency who was safely and successfully managed using rivaroxaban (a direct oral factor Xa inhibitor) during the perioperative period of surgery for right femur fracture. The present case illustrates the effectiveness of rivaroxaban in preventing thromboembolisms due to surgery, even in very elderly patients with antithrombin deficiency. Further investigations are needed to determine the optimal dosage of rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Kawai et al. (2017) conducted a case report in Antithrombin deficiency (n=1). Rivaroxaban was evaluated on Occurrence of thromboembolic events. Rivaroxaban successfully prevented thromboembolic events during the perioperative period in a 90-year-old woman with antithrombin deficiency, with no events occurring for at least three months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: